AU2022238365A1 - A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder - Google Patents

A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder Download PDF

Info

Publication number
AU2022238365A1
AU2022238365A1 AU2022238365A AU2022238365A AU2022238365A1 AU 2022238365 A1 AU2022238365 A1 AU 2022238365A1 AU 2022238365 A AU2022238365 A AU 2022238365A AU 2022238365 A AU2022238365 A AU 2022238365A AU 2022238365 A1 AU2022238365 A1 AU 2022238365A1
Authority
AU
Australia
Prior art keywords
compound
subject
treatment course
degrees
subsequent treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022238365A
Other languages
English (en)
Inventor
Bambang Senoaji Adiwijaya
James Doherty
Joi Lisa DUNBAR
Handan GUNDUZ-BRUCE
Jeffrey Martin JONAS
Stephen Jay KANES
Robert Alfonso LASSER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sage Therapeutics LLC
Original Assignee
Sage Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics LLC filed Critical Sage Therapeutics LLC
Publication of AU2022238365A1 publication Critical patent/AU2022238365A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2022238365A 2021-03-17 2022-03-17 A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder Pending AU2022238365A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163162501P 2021-03-17 2021-03-17
US63/162,501 2021-03-17
US202163284592P 2021-11-30 2021-11-30
US63/284,592 2021-11-30
PCT/US2022/020716 WO2022197901A1 (en) 2021-03-17 2022-03-17 A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder

Publications (1)

Publication Number Publication Date
AU2022238365A1 true AU2022238365A1 (en) 2023-09-21

Family

ID=81327141

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022238365A Pending AU2022238365A1 (en) 2021-03-17 2022-03-17 A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder

Country Status (11)

Country Link
US (1) US20240245711A1 (https=)
EP (1) EP4308162A1 (https=)
JP (1) JP2024510436A (https=)
KR (1) KR20230158033A (https=)
AU (1) AU2022238365A1 (https=)
BR (1) BR112023018607A2 (https=)
CA (1) CA3213744A1 (https=)
IL (1) IL305858A (https=)
MX (1) MX2023010728A (https=)
TW (1) TW202300156A (https=)
WO (1) WO2022197901A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP3504189A1 (en) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
MA51046A (fr) 2017-12-08 2021-03-17 Sage Therapeutics Inc Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102396328B1 (ko) * 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
EP3504189A1 (en) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
EP3612186A1 (en) * 2017-04-18 2020-02-26 Marinus Pharmaceuticals, Inc. Sustained release injectable neurosteroid formulations
WO2019051264A1 (en) * 2017-09-07 2019-03-14 Sage Therapeutics, Inc. NEUROACTIVE STEROIDS AND METHODS OF USE
CA3103421A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
KR20230041049A (ko) 2020-07-20 2023-03-23 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드의 제형 및 이의 사용 방법
US20230372364A1 (en) * 2020-10-01 2023-11-23 Jeremy Hill Method of treating gaba mediated disorders

Also Published As

Publication number Publication date
EP4308162A1 (en) 2024-01-24
BR112023018607A2 (pt) 2023-10-24
JP2024510436A (ja) 2024-03-07
MX2023010728A (es) 2024-02-12
WO2022197901A1 (en) 2022-09-22
TW202300156A (zh) 2023-01-01
US20240245711A1 (en) 2024-07-25
IL305858A (en) 2023-11-01
KR20230158033A (ko) 2023-11-17
CA3213744A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
US20240245711A1 (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder
US20250339447A1 (en) 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
AU2022267304A1 (en) Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female
US20240216395A1 (en) 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression
KR20240148425A (ko) Cns-관련 장애의 치료를 위한 신경활성 스테로이드
US20230018765A1 (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
WO2022061287A1 (en) TREATMENT OF NF-κB-MEDIATED DISEASE
CN117098554A (zh) 用于治疗重度抑郁障碍的19-去甲c3,3-二取代c21-n-吡唑基类固醇
CN117580581A (zh) 用于治疗重度抑郁障碍和产后抑郁症的19-去甲c3,3-二取代的c21-n-吡唑基类固醇
WO2025046421A1 (en) Methods of using factor b inhibitors

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: TO AMEND THE APPLICANT NAME TO SAGE THERAPEUTICS, LLC